Genomic Testing

FoundationFocus™ CDxBRCA

The first FDA-approved companion diagnostic for treatment of ovarian cancer with Rubraca™
  • Cancer Type
    Solid Tumor (Ovarian)
  • Biopsy Type
    FFPE
  • Results Expected
    2 Weeks

What is FoundationFocus CDxBRCA?

FoundationFocus CDxBRCA is the first FDA-approved companion diagnostic assay for the treatment of ovarian cancer with Rubraca™ (rucaparib), a PARP inhibitor therapy for BRCA-mutated ovarian cancer.

Conventional tests look only for germline alterations in blood or saliva. FoundationFocus CDxBRCA analyzes ovarian cancer tumor tissue to detect both germline (inherited) and somatic (acquired) BRCA1/2 mutation types associated with response to PARP inhibitor therapy.1,2

Indications, Contraindications, and Limitations

Overview

FoundationFocus CDxBRCA

  • 1 in 4

    women with ovarian cancer are BRCA+ (positive)

  • 50%

    Germline+ (positive)

  • 50%

    Somatic+ (positive)

  1. First FDA-approved Next-Generation Sequencing (NGS) companion diagnostic for Rubraca
  2. Uncovers more BRCA mutations with a single tissue test
  3. Can help identify more women 2-5 who may benefit from PARP inhibitor therapy

Publications

FoundationFocus CDxBRCA was used in Clovis Oncology, Inc.’s pivotal trial, ARIEL2. The assay was used to identify patients and to assess the ability of the assay to predict their response to Rubraca.

Published Clinical Study

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma

(ARIEL2 Part 1): an international, multicenter, open-label, Phase 2 trial

The Lancet Oncology (2016)

View the Published Paper

Published Clinical Study

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer

Annals of Oncology (2016)

View the Published Paper

Interested in learning more about how a Comprehensive Genomic Profiling test might help your patient? Our publications can help:

View all reports & validation

Order FoundationFocus CDxBRCA

We provide physicians with several options for ordering FoundationFocus CDxBRCA for patients, including online, fax, and e-mail. Healthcare providers must first complete a test requisition form to start the process and can expect results typically within 2 weeks from the time a specimen is received.

A doctor looking at the camera

Questions?
We’re here to help.

Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.

Contact

Patients

FoundationFocus CDxBRCA is ordered by your healthcare provider. Our patient info kit has all the information you and your doctor need to discuss FoundationFocus CDxBRCA testing.

Patient Info Kit (PDF)

We have even more to offer.

Learn more about our other tests, FoundationACT®, FoundationOne®, FoundationOne®Heme, or explore our insights partnerships.

  1. Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016 Aug;27(8):1449-55.
  2. Hennessy BTJ, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. JCO. 2010;28(22):3570-6.
  3. Pennington KP, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2013;20(3):764-75.
  4. Arts-de Jong M, et al. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. Eur J Cancer. 2016;(61):137-145.
  5. The ratio of germline to somatic BRCA alterations varies based on population studied.